TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA HUMAN FIBRIN GLUE (HFG) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PACKAGE FORM LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 INDUSTRY INSIGHTS
6 REGULATORY ANALYSIS
6.1.1 REGULATION IN U.S.
6.1.2 REGULATION IN EUROPE
6.1.3 REGULATION IN AUSTRALIA
6.1.4 REGULATION IN CANADA
6.1.5 REGULATION IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN TECHNOLOGICAL ADVANCEMENT
7.1.2 INCREASING SURGICAL PROCEDURES
7.1.3 ADVANTAGES OF HUMAN FIBRIN GLUE
7.1.4 INCREASE IN THE GERIATRIC POPULATION
7.1.5 SUPERIORITY OF FIBRIN SEALANTS, OVER LIMITATIONS OF CONVENTIONAL METHODS
7.2 RESTRAINTS
7.2.1 STRINGENT RULES & REGULATORY
7.2.2 HIGH COST OF PRODUCTS
7.2.3 RISK OF VIRAL INFECTIONS
7.3 OPPORTUNITIES
7.3.1 INCREASE IN PREVALENCE OF CHRONIC DISORDERS
7.3.2 RISE IN MINIMALLY INVASIVE SURGERIES
7.3.3 RISING PLASTIC SURGERIES
7.4 CHALLENGES
7.4.1 COMPLICATION RELATED TO USE OF HUMAN FIBRIN GLUE
7.4.2 LACK OF SKILLED PROFESSIONALS
7.4.3 DECREASED SURGICAL PROCEDURES DUE TO COVID-19
8 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA HUMAN FIBRIN GLUE (HFG) MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON SUPPLY CHAIN
8.3 IMPACT ON DEMAND
8.4 CONCLUSION
9 MIDDLE EAST AND AFRICA HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM
9.1 OVERVIEW
9.2 LIQUID
9.2.1 1-2 ML
9.2.2 7-10 ML
9.2.3 3-4 ML
9.2.4 5-6 ML
9.3 PATCH
9.4 OTHERS
10 MIDDLE EAST AND AFRICA HUMAN FIBRIN GLUE (HFG) MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 SPECIALTY CLINICS
10.4 AMBULATORY CARE CENTER
10.5 OTHERS
11 MIDDLE EAST AND AFRICA HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
12 MIDDLE EAST AND AFRICA HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 WOUND MANAGEMENT
12.3 BURN BLEEDING
12.4 PLASTIC SURGERY
12.5 GENERAL SURGERY
12.6 VASCULAR SURGERIES
12.7 LACERATIONS OF LIVER AND SPLEEN
12.8 CARDIAC SURGERY
12.9 PULMONARY SURGERY
12.10 ORTHOPEDIC SURGERIES
12.11 NEUROSURGERY
12.12 OTHERS
13 MIDDLE EAST AND AFRICA HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION
13.1 MIDDLE EAST & AFRICA
13.1.1 SAUDI ARABIA
13.1.2 SOUTH AFRICA
13.1.3 U.A.E
13.1.4 ISRAEL
13.1.5 EGYPT
13.1.6 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA HUMAN FIBRIN GLUE (HFG) MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 CSL LIMITED
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 JOHNSON & JOHNSON SERVICES, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 BAXTER
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 HUALAN BIOLOGICAL ENGINEERING, ING
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 SHANGHAI RAAS
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 CORZA HEALTH
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 MARQUEE BIOSURGICAL
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.